How Long Should You Stay on GLP-1 Medications?

By Dr. Quoc N. Dang, DO — Medical Director, WeightLossPills.com

It usually comes up around the six-month mark.

A patient is doing well. The weight is moving. The side effects have settled. Things are working the way we hoped. And then, almost reflexively, they ask: “So… how long am I going to be on this?”

Sometimes the question is practical. Insurance is expensive, the medication is expensive, and they want to know when they can stop paying for it. Sometimes it’s more philosophical. There’s something uncomfortable, for some people, about the idea of being on a medication indefinitely. They associate that with chronic disease in a way that doesn’t match how they see themselves.

And sometimes they’ve read something online, or a friend told them that you only need it for a year, and they want to know if that’s true.

The honest answer is more complicated than most patients want it to be. But it’s worth getting right, because decisions made at this point in treatment often determine whether the results stick or gradually reverse.

The weight regain data is something patients need to see

There is a study I come back to fairly often in these conversations. It’s the STEP 4 trial extension, published in JAMA in 2022. Patients who had been on semaglutide for about 20 weeks — losing meaningful weight during that period — were then randomized to either continue the medication or switch to placebo for another year.

The patients who continued semaglutide kept losing weight, or at least maintained most of what they’d lost.

The patients who switched to placebo regained, on average, about two-thirds of the weight they had lost over the prior 20 weeks.

That is not a subtle finding. And it tells you something important: the medication was doing a lot of the work. Not all of it. But enough that removing it, without something in place to compensate, produced rapid reversal.

I share this data not to discourage patients from ever stopping. I share it because people make better decisions when they understand what they’re actually deciding. Stopping a GLP-1 medication is not like stopping an antibiotic when an infection clears. The underlying condition — the dysregulated appetite signaling, the hormonal environment that makes weight gain easy and weight maintenance hard — does not resolve during treatment. It is being managed.

Obesity is a chronic condition, not a temporary problem

This framing matters more than people initially think.

We do not expect someone to take blood pressure medication for a year and then stop because their pressure is now controlled. The medication controls it. That’s not the same as curing the underlying tendency. Most patients with hypertension understand this intuitively after a while.

Obesity medicine has been slow to get to that same place, for a lot of reasons, many of them cultural. There is still a persistent belief, among patients and sometimes among clinicians, that weight loss is something you achieve and then maintain through discipline alone. The biology says otherwise.

When someone with obesity loses significant weight, the body responds by increasing hunger signals, reducing metabolic rate, and creating hormonal conditions that favor weight regain. These adaptations are not a character flaw. They are physiological responses that researchers have documented clearly over decades. GLP-1 medications intervene in that system. But they do not rewire it permanently.

So the starting point for any honest conversation about duration is this: if you stop the medication, the biology that made weight loss difficult in the first place does not disappear. Whether you can sustain results without it depends on a lot of individual factors, and the honest answer is that most people cannot sustain the same level of weight loss long-term without continued support of some kind.

That said, stopping is not always the wrong decision

I want to be clear that I am not arguing every patient should be on a GLP-1 indefinitely. That is not the point.

There are patients who come off GLP-1 therapy and maintain their results reasonably well. They tend to share a few things in common. They have made durable changes to their eating patterns — not just eating less while the medication suppresses appetite, but actually building different habits around food that continue after the medication is gone. They exercise regularly and have made it a consistent part of how they live, not just a weight loss strategy. Their lifestyle outside of medication — sleep, stress, routine — is reasonably stable.

And honestly, some of them are just fortunate in terms of where their biology lands after significant weight loss. There is individual variation in how aggressively the body fights to return to a previous set point.

But even in these cases, I ask patients to be clear-eyed about the decision. “Stopping because you’ve hit your goal and want to see if you can maintain it” is a very different conversation than “stopping because the cost is unsustainable and you’re hoping for the best.” One is a reasonable clinical decision. The other often leads back to my office six to eighteen months later.

The lifestyle piece is not a supplement to the medication. It is the infrastructure.

There is a version of GLP-1 therapy that goes poorly over the long term, and it usually looks like this: a patient takes the medication, loses weight steadily, and attributes the results almost entirely to the drug. They do not fundamentally change how they eat. They do not establish a consistent exercise routine. When the medication eventually becomes unaffordable, unavailable, or something they decide to stop, there is very little structure in place to hold the results.

I see this more than I would like to. Not because patients are not trying, but because the medication works so well that motivation to build underlying habits can actually decrease. Why work on the basics when the drug is handling it?

The answer is: because the drug is not going to be there forever for everyone. And even for patients who remain on it indefinitely, the lifestyle factors make the medication work better. Patients who exercise regularly and eat adequate protein preserve more lean mass, maintain better metabolic function, and tend to feel qualitatively better throughout treatment.

When I counsel patients on the duration question, I often redirect it slightly. The question is not just how long to stay on the medication. It is what you are building during the time the medication is giving you an advantage. The window of reduced hunger and strong motivation is a real opportunity. What you do with it determines a lot about what happens next.

When stopping makes sense and how to do it thoughtfully

If a patient is considering stopping GLP-1 therapy, I want that to be a planned conversation, not something that happens because a prescription ran out or a prior authorization lapsed.

A few things I look for before endorsing a trial off medication: the patient has been at or near their goal weight for a meaningful period, not just recently arrived. Their eating patterns have genuinely changed, not just while the medication suppressed appetite but as a matter of how they consistently approach food. They have a regular exercise routine in place, specifically including resistance training. And they have a realistic understanding of what to watch for and what “restart” criteria look like if things drift.

I also usually recommend tapering where the dose schedule allows for it, rather than abrupt discontinuation. Abrupt stopping can lead to more pronounced rebound hunger and a harder psychological adjustment than a gradual reduction.

And I ask patients to set a specific weight threshold in advance. Not a vague commitment to “watching it.” A specific number at which point they will contact me and we will discuss next steps, whether that means returning to medication, intensifying lifestyle support, or something else. Having that threshold defined while the patient is in a clear-headed place, rather than after several months of gradual regain, makes a real difference.

The cost and access reality deserves an honest conversation too

I would be leaving out something important if I did not acknowledge that for many patients, duration is not purely a clinical decision. It is a financial one.

GLP-1 medications are expensive. Insurance coverage is inconsistent and often requires ongoing prior authorization battles. Patients who do not have reliable coverage face a cost that most cannot sustain indefinitely. That is a real constraint, and pretending otherwise does not help anyone.

What I try to do in those situations is be honest about the trade-off rather than avoiding it. If a patient needs to stop for financial reasons, we can be strategic about how we do it and what we put in place. If they are researching options for more affordable access, including whether lower doses or different formulations make financial sense for their situation, that is a legitimate conversation.

People who are already looking into options for weight loss pills online often ask whether compounded versions or older generic alternatives provide a reasonable bridge. It is worth understanding the full landscape of what is available and what the evidence supports before making those decisions without guidance.

There is no single right answer, but there is a right process

I cannot tell a patient at month six how long they will need this medication. Nobody can. What I can tell them is what the data shows about the consequences of stopping, what factors seem to predict better outcomes in patients who do come off medication, and what we would want in place before trying.

What I try to avoid is the conversation becoming about ideology. Some patients have a strong prior that medication is a crutch and that real success means eventually doing it without pharmacological support. I understand that feeling. But we do not think about blood pressure medication or thyroid medication that way. The question is whether the condition is being managed and whether the patient is healthy. The means matters less than the outcome.

Other patients come in assuming they will be on a GLP-1 forever and have not really thought about what they are building in the meantime. Those conversations go a different direction.

The patients who tend to do best, regardless of whether they eventually stay on medication or transition off, are the ones who treat the treatment period as a time to build something durable. Not just to lose weight, but to create a way of living that does not depend entirely on a drug to function.

That is an achievable goal. It takes real effort and real intention. But the medication buys you time and reduces the friction enough that it is more achievable than it would be otherwise. What you do with that window matters enormously.

If you are currently on a GLP-1 medication and wondering about your next steps, or if you are in the early stages of exploring whether this class of treatment is appropriate for your situation, the most important thing is to have that conversation with a physician who understands the full picture. Not just the drug, but everything that determines whether results are going to last.

Dr. Quoc N. Dang, DO, is a board certified physician and Medical Director at WeightLossPills.com, where he specializes in medically supervised weight management and GLP-1 therapy.